B+
Bull case
25%
Probability
Target price
$56.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
SNY
SanofiANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Strong Q2 execution, rapid Dupixent growth, launch momentum, free-cash-flow improvement, and upgraded 2026 guidance support a constructive medium-term setup. The supplied median analyst target of $50.60 implies approximately 18.6% upside from the $42.68 anchor price.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.5.
What can break
Clinical, regulatory, safety, manufacturing, competitive, and pricing risks across the biopharma portfolio.
Momentum
30
Value
70
Sentiment
78
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $49.00 · Bull $56.00 · Bear $37.00Analysis 2026-08-05; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $50.00
Why
Momentum30 · Δ7d +6.7
Value70 · Δ7d -0.0
Sentiment78 · Δ7d +10.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +10.5.
Contradictions & invalidation
- • Clinical, regulatory, safety, manufacturing, competitive, and pricing risks across the biopharma portfolio.
- • Continued reliance on Dupixent and successful execution of newer pharmaceutical launches.
- • Forward visibility remains limited despite the guidance upgrade.
Catalyst clock
2026-07-30
Q2 growth and 2026 guidance upgrade
Lead driver: Sentiment · See AI snapshot
Momentum
30
9% active weight
Current posture
7d trendImproving
Δ7d
+6.7
Δ21d
-3.3
Value
70
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.9
Sentiment
78
62% active weight
Current posture
7d trendImproving
Δ7d
+10.5
Δ21d
+7.7
Why this grade
Composite grade A. Momentum 29.6 / Value 69.6 / Sentiment 77.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-05. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$49.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$106.48B
Beta
0.43
Shares Out
2.38B
P/E (TTM)
16.1
P/S (TTM)
2.35
P/FCF (TTM)
97.54
Rev YoY
-7.0%
EPS YoY
+3.1%
Gross Margin
+66.3%
Op Margin
+27.2%
Net Debt
$14.86B
Current Ratio
0.99
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data